Scientists test 'Living Drug' to reboot immune system in tough lupus cases
NCT ID NCT06465147
Summary
This early-stage study is testing a new cell therapy for children and young adults with severe lupus that hasn't responded to other treatments. Doctors will collect a patient's own T cells, genetically modify them in a lab to target harmful B cells, and then infuse them back. The main goals are to see if this process is safe and possible, and to look for early signs that it might help control the disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Seattle Children's Hospital
RECRUITINGSeattle, Washington, 98105, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.